Isfahan University of Medical Sciences Journal of Isfahan Medical School 1027-7595 42 771 2024 07 22 Comparison of Radiotherapy and Cold Plasma Treatment Approaches in Inhibiting the Growth of Cancer Cells Comparison of Radiotherapy and Cold Plasma Treatment Approaches in Inhibiting the Growth of Cancer Cells 483 488 31264 10.48305/jims.v42.i771.0483 FA Sara Momeni Assistant Professor, Department of Radiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences AND Assistant Professor, Department of Medical Physics and Radiological Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran 0000-0002-6392-7239 Ahmad Shanei Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0001-5999-0932 Journal Article 2024 07 09 Background: Radiotherapy is a prevalent modality for treating cancer; however, certain cancers, such as melanoma, exhibit resistance to ionizing radiation. Cold plasma, an emerging technology in the field of medical science, is currently under scrutiny for its unique properties. The primary objective of this research was to compare the efficacy of radiotherapy and cold plasma as treatment modalities for melanoma and healthy fibroblast cell lines. Methods: Melanoma cancer cells (DFW) and healthy fibroblasts (HFF) were exposed to radiotherapy doses of 1, 2, and 4 Gy, as well as cold plasma radiation for varying durations of 15, 30, 60, and 90 seconds. Subsequently, the outcomes of the MTT assay were compared. Furthermore, the level of apoptosis in each group was assessed utilizing flow cytometry. Findings: While the survival percentage in melanoma cells treated with radiotherapy did not significantly change compared to the control group, even at high doses, it reached 36% in cells treated with cold plasma. The survival rate in healthy cells reached 70% in high radiation doses, while in the treatment with cold plasma, no significant difference was observed even in long plasma irradiation times. Conclusion: The present study confirmed the anticancer and selectivity properties of cold plasma in treating melanoma cells. Compared with radiotherapy and cold plasma, cold plasma shows better performance than radiotherapy in melanoma cell treatment. Background: Radiotherapy is a prevalent modality for treating cancer; however, certain cancers, such as melanoma, exhibit resistance to ionizing radiation. Cold plasma, an emerging technology in the field of medical science, is currently under scrutiny for its unique properties. The primary objective of this research was to compare the efficacy of radiotherapy and cold plasma as treatment modalities for melanoma and healthy fibroblast cell lines. Methods: Melanoma cancer cells (DFW) and healthy fibroblasts (HFF) were exposed to radiotherapy doses of 1, 2, and 4 Gy, as well as cold plasma radiation for varying durations of 15, 30, 60, and 90 seconds. Subsequently, the outcomes of the MTT assay were compared. Furthermore, the level of apoptosis in each group was assessed utilizing flow cytometry. Findings: While the survival percentage in melanoma cells treated with radiotherapy did not significantly change compared to the control group, even at high doses, it reached 36% in cells treated with cold plasma. The survival rate in healthy cells reached 70% in high radiation doses, while in the treatment with cold plasma, no significant difference was observed even in long plasma irradiation times. Conclusion: The present study confirmed the anticancer and selectivity properties of cold plasma in treating melanoma cells. Compared with radiotherapy and cold plasma, cold plasma shows better performance than radiotherapy in melanoma cell treatment.

https://jims.mui.ac.ir/article_31264_56909640f93a509bda9494a0178e091e.pdf

Isfahan University of Medical Sciences Journal of Isfahan Medical School 1027-7595 42 771 2024 07 22 Evaluation of the Effect of Ionic Plasma Cluster Technology on the Improvement of Symptoms in Patients with COVID-19 Evaluation of the Effect of Ionic Plasma Cluster Technology on the Improvement of Symptoms in Patients with COVID-19 489 496 31265 10.48305/jims.v42.i771.0489 FA Mohammad Reza Taghavi Assistant Professor of Infectious Disease, North Khorasan University of Medical Sciences, Bojnurd, Iran 0000-0003-3182-2739 Mohammad Hossein Karamouz Mashhadi BS of Nurse in Imam Hasan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran 0000-0002-3974-2170 Salar Poorbarat BS of Nurse in Imam Hasan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran 0000-0002-2506-7960 Emad Khoshdel Department of Medical Physics, School of Medicine,Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran 0000-0001-5924-4366 Mohamad Amin Younessi Heravi Assistant Professor of Medical Physics and Radiology, North Khorasan University of Medical Sciences, Bojnurd, Iran 0000-0002-7960-3095 Journal Article 2024 02 07 Background: Fever, gastrointestinal symptoms, lethargy and weakness, headache, shortness of breath, and cough are usually clinical symptoms of COVID-19. This study aimedto investigate the effect of plasma cluster in improving the clinical symptoms of patients with COVID-19. Methods: This study was a double-blind clinical trial that was conducted on patients with COVID-19at Imam Hassan (AS) Bojnurd Hospital. In the intervention group, the plasma clusters device was turned on continuously for 8 hours and then turned off. In the control group, the device was placed in the room, and the ionization part of the device was removed from the circuit. Patients were monitored for five days after the intervention in terms of improvement of clinical symptoms. Data analysis was done with T, χ2, and variance tests in repeated measures. Findings: The results showed that fever on the first day and weakness and lethargy on the first and third days of the disease showed a significant decrease compared to the beginning. Other clinical symptoms of the patient did not show any significant difference in the two groups. Also, the clinical symptoms showed significant changes in the improvement of the symptoms of COVID-19 in the intervention group compared to the control group. However, there was no significant difference in body temperature between the two groups. Conclusion: Therefore, along with routine treatments, the cold plasma device can be helpful as an auxiliary factor in improving patients' symptoms and treating them faster. Background: Fever, gastrointestinal symptoms, lethargy and weakness, headache, shortness of breath, and cough are usually clinical symptoms of COVID-19. This study aimedto investigate the effect of plasma cluster in improving the clinical symptoms of patients with COVID-19. Methods: This study was a double-blind clinical trial that was conducted on patients with COVID-19at Imam Hassan (AS) Bojnurd Hospital. In the intervention group, the plasma clusters device was turned on continuously for 8 hours and then turned off. In the control group, the device was placed in the room, and the ionization part of the device was removed from the circuit. Patients were monitored for five days after the intervention in terms of improvement of clinical symptoms. Data analysis was done with T, χ2, and variance tests in repeated measures. Findings: The results showed that fever on the first day and weakness and lethargy on the first and third days of the disease showed a significant decrease compared to the beginning. Other clinical symptoms of the patient did not show any significant difference in the two groups. Also, the clinical symptoms showed significant changes in the improvement of the symptoms of COVID-19 in the intervention group compared to the control group. However, there was no significant difference in body temperature between the two groups. Conclusion: Therefore, along with routine treatments, the cold plasma device can be helpful as an auxiliary factor in improving patients' symptoms and treating them faster.

https://jims.mui.ac.ir/article_31265_fa68a633df6169bb2bf730da98faff59.pdf

Isfahan University of Medical Sciences Journal of Isfahan Medical School 1027-7595 42 771 2024 07 22 A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial 497 510 31261 10.48305/jims.v42.i771.0497 FA Masoumeh Sadeghi Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0001-7179-5558 Hamidreza Roohafza MD, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0003-3582-0431 Alireza Nateghi Pharmacist, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran Nizal Sarrafzadegan Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0002-8352-0540 Marjan Mansourian Professor, Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Jamshid Najafian Associate Professor, Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0002-1472-1218 Fatemeh Bostan MD, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Shervin Ghaffari Hoseini Assistant Professor, Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 0000-0003-4340-8949 Journal Article 2024 06 05 Background: This article is an update on our previous review of clinical studies on the role of polypills in the secondary prevention of cardiovascular diseases (CVD). We also present the preliminary results of the Persian Polypill study. Methods: Persian Polypill is a randomized clinical trial with two parallel arms on hospitalized patients due to acute myocardial infarction (AMI). It is planned that 1100 patients will be randomly assigned to one of the two arms of Polypill or usual care and will be followed up for 34 months. The primary outcome will be a composite clinical outcome of major adverse cardiovascular events (MACE), and the secondary outcome will be the cost-effectiveness of polypill treatment. Findings: We identified ten completed studies and two ongoing trials in which at least 10% of participants had CVD. The evaluation of these studies showed the lack of research in low- and middle-income countries about the role of polypill in secondary prevention of CVD and limited information about cost-effectiveness resulting from clinical trials. In Persian Polypill, so far, 624 patients admitted to three hospitals due to AMI have been included in the study. The average age of patients is 60.9 ± 8.7 and 506 are male (81.1%). Overall, 94.4% of the patients underwent percutaneous coronary intervention in the hospital, and 26.3% had hospital complications. Conclusion: The final results of this study can compensate for the gap in the past studies. They may confirm the role of polypill in the initial management of AMI and long-term secondary prevention in these patients. Background: This article is an update on our previous review of clinical studies on the role of polypills in the secondary prevention of cardiovascular diseases (CVD). We also present the preliminary results of the Persian Polypill study. Methods: Persian Polypill is a randomized clinical trial with two parallel arms on hospitalized patients due to acute myocardial infarction (AMI). It is planned that 1100 patients will be randomly assigned to one of the two arms of Polypill or usual care and will be followed up for 34 months. The primary outcome will be a composite clinical outcome of major adverse cardiovascular events (MACE), and the secondary outcome will be the cost-effectiveness of polypill treatment. Findings: We identified ten completed studies and two ongoing trials in which at least 10% of participants had CVD. The evaluation of these studies showed the lack of research in low- and middle-income countries about the role of polypill in secondary prevention of CVD and limited information about cost-effectiveness resulting from clinical trials. In Persian Polypill, so far, 624 patients admitted to three hospitals due to AMI have been included in the study. The average age of patients is 60.9 ± 8.7 and 506 are male (81.1%). Overall, 94.4% of the patients underwent percutaneous coronary intervention in the hospital, and 26.3% had hospital complications. Conclusion: The final results of this study can compensate for the gap in the past studies. They may confirm the role of polypill in the initial management of AMI and long-term secondary prevention in these patients.

https://jims.mui.ac.ir/article_31261_5d5ef971a832156872b8ae6732280d0a.pdf